United Therapeutics (UTHR) Gross Profit (2009 - 2026)

United Therapeutics has disclosed Gross Profit across 18 years of filings, most recently posting $683.8 million for Q2 2026.

• In Q2 2026, Gross Profit fell 3.83% year-over-year to $683.8 million; the TTM figure through Jun 2026 stood at $2.7 billion (down 0.78% YoY), while the FY2025 annual figure was $2.8 billion, up 8.98% from the prior year.
• Gross Profit came in at $683.8 million for Q2 2026 at United Therapeutics, up from $648.1 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $711.0 million in Q2 2025 to a low of $432.7 million in Q4 2022.
• Average Gross Profit over 5 years is $586.3 million, with a median of $620.9 million recorded in 2024.
• Year-over-year, Gross Profit jumped 33.04% in 2024 and declined 7.66% in 2026.
• Over 5 years, Gross Profit stood at $432.7 million in 2022, then rose by 25.65% to $543.7 million in 2023, then climbed by 21.39% to $660.0 million in 2024, then advanced by 4.06% to $686.8 million in 2025, then retreated by 0.44% to $683.8 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $683.8 million in Q2 2026, $648.1 million in Q1 2026, and $686.8 million in Q4 2025.